Getinge reports 18% drop in core earnings amid tariff pressures By Investing.com

The headline is less about one healthcare printer and more about a prolonged capex freeze across regulated industrial end markets. When customers defer project-based spend, suppliers with a high mix of consumables and recurring service usually outperform pure equipment vendors; that implies the pain should persist longer for peers with similar large-ticket exposure and stronger near-term order elasticity than for broad-line medtech names. The pricing pass-through is supportive over a 2-4 quarter horizon, but the lag means margins can still be mechanically compressed even if volume stabilizes, especially while FX remains a headwind.

The second-order effect is on supply-chain behavior: higher tariffs and geopolitical uncertainty incentivize more localized sourcing, dual-sourcing, and inventory buffering, which lifts working capital and delays normalization of free cash flow. That tends to benefit contract manufacturers, regional suppliers, and firms with U.S.-based production footprints, while pressuring globally optimized exporters that lack pricing power. The bigger risk is not a one-quarter miss; it is a slower recovery in hospital and pharma capex if CFOs treat trade policy as structurally unstable rather than transitory.

Contrarian angle: the market may be overestimating how permanent the demand deferral is. Healthcare sterilization and ICU infrastructure are not discretionary in the long run, so once procurement visibility improves, order growth can reaccelerate quickly from a low base. But until tariffs and FX stop whipsawing earnings, the stock can remain a “good business, bad optics” name—meaning multiple expansion likely lags fundamental stabilization by at least 1-2 quarters.